Amphastar Pharmaceuticals (AMPH) Stock Overview
A bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
AMPH Community Fair Values
Create NarrativeSee what 44 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
Read full narrativeAmphastar Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.90 |
| 52 Week High | US$31.26 |
| 52 Week Low | US$17.03 |
| Beta | 0.97 |
| 1 Month Change | 16.13% |
| 3 Month Change | -16.52% |
| 1 Year Change | -2.17% |
| 3 Year Change | -41.98% |
| 5 Year Change | 25.26% |
| Change since IPO | 138.76% |
Recent News & Updates
Amphastar: A Cheap Multiple Doing Exactly What It's Supposed To Do
Apr 30
AMPH: Revised Outlook Suggests Future Upside As New Therapies Scale
Narrative Update on Amphastar Pharmaceuticals The analyst price target for Amphastar Pharmaceuticals has shifted from $38 to $30 as analysts factor in revised revenue guidance, lower projected profit margins, and a higher assumed future P/E multiple. They also note the potential importance of AMP-007 for achieving mid to high single digit revenue growth targets.
AMPH: Share Repurchases And New Launches Will Support Future Upside Potential
Analysts have trimmed Amphastar Pharmaceuticals' fair value estimate by $1 to about $28, reflecting lower Street price targets and cautious views on revised revenue guidance despite recent product approvals. Analyst Commentary Recent Street research on Amphastar shares points to a more cautious tone after the latest revenue guidance update and lower price targets, even as new products move through the approval pipeline.Recent updates
Amphastar: A Cheap Multiple Doing Exactly What It's Supposed To Do
Apr 30AMPH: Revised Outlook Suggests Future Upside As New Therapies Scale
Narrative Update on Amphastar Pharmaceuticals The analyst price target for Amphastar Pharmaceuticals has shifted from $38 to $30 as analysts factor in revised revenue guidance, lower projected profit margins, and a higher assumed future P/E multiple. They also note the potential importance of AMP-007 for achieving mid to high single digit revenue growth targets.AMPH: Share Repurchases And New Launches Will Support Future Upside Potential
Analysts have trimmed Amphastar Pharmaceuticals' fair value estimate by $1 to about $28, reflecting lower Street price targets and cautious views on revised revenue guidance despite recent product approvals. Analyst Commentary Recent Street research on Amphastar shares points to a more cautious tone after the latest revenue guidance update and lower price targets, even as new products move through the approval pipeline.AMPH: Softer Guidance And Execution Risk Will Shape Future Upside Potential
Analysts have trimmed Amphastar Pharmaceuticals' fair value estimate from $32.00 to $29.00. This reflects updated views on softer revenue guidance, lower projected profit margins, a slightly higher discount rate, and a higher assumed future P/E multiple in light of recent price target cuts to $30.00 from several firms.
AMPH: Softer Guidance And Pipeline Risk Will Still Support Future Upside
Analysts have modestly reduced their price targets on Amphastar Pharmaceuticals to $30, reflecting concerns about softer revenue guidance and pipeline execution risk. At the same time, recent product approvals and revised earnings assumptions support a slightly higher modeled fair value and P/E multiple in our framework.AMPH: Pipeline Execution Risk Will Cap Upside Despite Lowered US$30 Outlook
Analysts have trimmed their price target on Amphastar Pharmaceuticals to $30 from $31, citing cautious views on pipeline execution risk, even as they still see the shares as undervalued relative to peers and historical valuation. Analyst Commentary Recent research updates reflect a more cautious tone, with bearish analysts trimming price expectations even while acknowledging that Amphastar still trades at what they view as a discount to peers and its own history.AMPH: Pipeline Execution Risk Will Drive Cautious View Despite Lowered US$30 Outlook
Analysts have trimmed their price target on Amphastar Pharmaceuticals to US$30 from US$31, reflecting a cautious view on pipeline execution risk, even as they see the shares as undervalued relative to historical and peer valuations. Analyst Commentary Bearish analysts have trimmed their price target on Amphastar Pharmaceuticals to US$30 from US$31 as coverage transitions, signaling a cautious stance on how the company can deliver on its current pipeline while justifying its valuation.AMPH: Buybacks And Pipeline Risk Will Shape Cautious Yet Balanced Outlook
Analysts have trimmed their price target on Amphastar Pharmaceuticals to $30 from $31, reflecting updated views on revenue growth, margin assumptions, and future P/E expectations, along with ongoing caution around pipeline execution risk. Analyst Commentary Bearish analysts have taken a slightly more cautious stance, trimming the price target to US$30 from US$31 as coverage transitions to a new lead.AMPH: Pipeline Execution Risk Will Shape Cautious View Despite Buybacks
Analysts have trimmed their price target on Amphastar Pharmaceuticals to $30 from $31. The revised target reflects fresh coverage that balances a view of the shares as undervalued on comps and historical valuation with caution around pipeline execution risk.AMPH: Q3 Drug Trends And Buybacks Will Shape Balanced Near-Term Outlook
Analysts have modestly lowered their price target on Amphastar Pharmaceuticals to $31 from $32, citing recent Q3 pricing and volume trends for key drugs and a largely unchanged outlook for near term earnings and 2026 estimates. Analyst Commentary Bearish analysts have highlighted that the modest reduction in the price target reflects growing caution around the durability of Amphastar's recent performance, particularly in light of more muted pricing and volume trends observed in the third quarter.Earnings Working Against Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Share Price
Jul 01
We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Stay On Top Of Its Debt
Apr 04Amphastar Pharmaceuticals: A Gradual Strategy
Feb 19These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Reasonably Well
Jan 03Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Prospects Need A Boost To Lift Shares
Dec 16Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors
Nov 28Amphastar: Objectively Undervalued But For Good Reason (Rating Downgrade)
Oct 25Investors Continue Waiting On Sidelines For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)
Sep 15Amphastar: Perplexing Pipeline, Lumpy Revenues - I'm On Sidelines
Sep 12
Decisive Acquisitions And Production Innovations Propel Pharma Growth And Market Dominance
Emphasis on proprietary products and strategic acquisitions to enhance market presence and contribute significantly to revenue growth.Is Amphastar Pharmaceuticals (NASDAQ:AMPH) Using Too Much Debt?
Aug 27Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?
Jul 05Amphastar Pharmaceuticals: Shining Star Soon To Fade With Competitive Pressures Looming
Jul 01Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Subdued P/E Might Signal An Opportunity
May 30Amphastar Pharmaceuticals: Buy When Fear Is Overblown
May 30Reassessing Amphastar Pharmaceuticals
May 15Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet
Mar 27Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions
Mar 04Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today
Jan 04Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E
Dec 20Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet
Dec 03Amphastar Pharmaceuticals (NASDAQ:AMPH) Ticks All The Boxes When It Comes To Earnings Growth
Sep 18Shareholder Returns
| AMPH | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 10.5% | 5.1% | 1.8% |
| 1Y | -2.2% | 34.5% | 29.8% |
Return vs Industry: AMPH underperformed the US Pharmaceuticals industry which returned 34.5% over the past year.
Return vs Market: AMPH underperformed the US Market which returned 29.8% over the past year.
Price Volatility
| AMPH volatility | |
|---|---|
| AMPH Average Weekly Movement | 9.0% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: AMPH has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AMPH's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 1,976 | Jack Zhang | www.amphastar.com |
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate.
Amphastar Pharmaceuticals, Inc. Fundamentals Summary
| AMPH fundamental statistics | |
|---|---|
| Market cap | US$1.04b |
| Earnings (TTM) | US$98.09m |
| Revenue (TTM) | US$719.89m |
Is AMPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMPH income statement (TTM) | |
|---|---|
| Revenue | US$719.89m |
| Cost of Revenue | US$363.83m |
| Gross Profit | US$356.06m |
| Other Expenses | US$257.96m |
| Earnings | US$98.09m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 07, 2026
| Earnings per share (EPS) | 2.20 |
| Gross Margin | 49.46% |
| Net Profit Margin | 13.63% |
| Debt/Equity Ratio | 77.3% |
How did AMPH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/06 21:56 |
| End of Day Share Price | 2026/05/06 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Amphastar Pharmaceuticals, Inc. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Glen Santangelo | Barclays |
| Gary Nachman | BMO Capital Markets Equity Research |
| Pavan Patel | BofA Global Research |